Research programme: rheumatoid arthritis fusion protein therapeutics - Alkermes
Alternative Names: ALKS 6931Latest Information Update: 01 Dec 2021
At a glance
- Originator Alkermes
- Developer Alkermes plc
- Class Proteins
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 22 Nov 2021 Acceleron Pharma has been acquired by Merck & Co
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)